[20210913]IF11858_潜在的WTO TRIPS豁免和2019冠状病毒疾病.pdf

上传人:任我行 文档编号:31149 上传时间:2022-06-24 发布时间:2021-09-17 格式:PDF 页数:3 大小:541.77KB
下载 相关 举报
[20210913]IF11858_潜在的WTO TRIPS豁免和2019冠状病毒疾病.pdf_第1页
第1页 / 共3页
[20210913]IF11858_潜在的WTO TRIPS豁免和2019冠状病毒疾病.pdf_第2页
第2页 / 共3页
[20210913]IF11858_潜在的WTO TRIPS豁免和2019冠状病毒疾病.pdf_第3页
第3页 / 共3页
亲,该文档总共3页,全部预览完了,如果喜欢就下载吧!
资源描述

1、 https:/crsreports.congress.gov Updated September 13, 2021Potential WTO TRIPS Waiver and COVID-19The Coronavirus Disease 2019 (COVID-19) pandemic has spurred biopharmaceutical companies to conduct costly and risky research and development (R&D) to develop vaccines and other products to respond to CO

2、VID-19. Firms have relied on intellectual property rights (IPR) to commercialize these products. Governments and nonprofits have funded and coordinated some of the underlying R&D. Some groups have voiced concerns over the impact of IPR on affordable access to these products for low- and middle-incom

3、e countries (LMICs). On May 5, 2021, the Biden Administration announced its support for the concept of a waiver of parts of the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) for COVID-19 vaccines, and pledged to “actively participate in tex

4、t-based negotiations at the WTO to make that happen.” Many consider this notable, given the United States history of advancing IPR standards globally. Members of Congress are divided on the issue. An active debate is underway in the WTO on the role of IPR and trade policy in the pandemic response. B

展开阅读全文
相关资源
猜你喜欢
相关搜索
资源标签

当前位置:首页 > 法规条令 > CRS 美国国会研究处报告